## ASO VISUAL ABSTRACT


## ASO Visual Abstract: Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention

Loryn K. Bucci, BS<sup>1</sup>, Cheryl L. Brunelle, MScPT<sup>2</sup>, Madison C. Bernstein, BA<sup>1</sup>, Amy M. Shui, MA<sup>3</sup>, Tessa C. Gillespie, BS<sup>1</sup>, Sacha A. Roberts, BS<sup>1</sup>, George E. Naoum, MD<sup>1</sup>, and Alphonse G. Taghian, MD, PhD, FASTRO<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA; <sup>2</sup>Department of Physical and Occupational Therapy, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Biostatistics Center, Massachusetts General Hospital, Boston, MA

Breast cancer-related lymphedema (BCRL) is a complication of breast cancer treatment. Identifying subclinical lymphedema (SCL) may prevent BCRL, as patients with SCL after axillary nodal surgery are more likely to progress to BCRL than those who do not develop SCL (https://doi.org/10.1245/s10434-021-10173-0).

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© Society of Surgical Oncology 2021

Published Online: 23 May 2021 A. G. Taghian, MD, PhD, FASTRO

e-mail: ataghian@partners.org; ataghian@mgh.harvard.edu